MannKind Corp (NASDAQ:MNKD)
A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Recs
siri22
(< 20)
Submitted: 2/3/2012 2:31:00 PM :
Start Price:
$2.15
MNKD Score:
+8.43
hopefully near bottom for this speculative stock, with great idea
Recs
TheWBWay
(77.72)
Submitted: 1/26/2012 4:39:40 PM :
Start Price:
$3.34
MNKD Score:
-32.62
something big is brewing, just broke the 200 DMA. This little stock could shoot up to a hundred per share in a matter of months. Huge upside potential and small downside since the stock is only at $3.41 as I make this post.
Recs
PharmaEQ2xBeta
(51.62)
Submitted: 1/8/2012 12:53:06 PM :
Start Price:
$2.56
MNKD Score:
-13.95
Major catalyst coming in 2013. Dreamboat will prevail!
Recs
AirHead12345678
(< 20)
Submitted: 11/16/2011 10:07:23 AM :
Start Price:
$3.03
MNKD Score:
-30.63
No other durg availble, to provide reduced need for insulin , while maintaining levels and reducing hyopoclimcama
Recs
Dwest15
(53.44)
Submitted: 10/7/2011 11:36:22 PM :
Start Price:
$3.42
MNKD Score:
-46.05
Mannkind is developing inhalable insulin for type I and type II diabetes for distribution to the US and European Markets. Once MNKD receives approval from the FDA and EU regulators, their product and stock will take off.
Recs
modestus1
(< 20)
Submitted: 8/13/2011 10:57:22 PM :
Start Price:
$2.91
MNKD Score:
-32.66
drug speculation
Recs
ipsiety
(26.58)
Submitted: 6/22/2011 2:55:43 PM :
Start Price:
$4.07
MNKD Score:
+46.71
Speculation at the moment.
Recs
GreenCollegeGrad
(78.16)
Submitted: 3/9/2011 9:16:20 PM :
Start Price:
$3.79
MNKD Score:
-41.64
MannKind corporation, a S+P four star rated stock, is awaiting the FDA to approve its star in the making, an inhaled insulin named Afrezza. Though biotech can be risky this play is certainly worth taking a gamble on, especially when S+P rates a fair value at 5.50 and a "consider selling" price at 11. Gonna hve to reccomend this one
Recs
rocknpopstocks
(< 20)
Submitted: 2/26/2011 6:50:41 PM :
Start Price:
$3.67
MNKD Score:
-37.67
Could see major upside with good news.
Recs
Charlie9665
(< 20)
Submitted: 2/11/2011 1:43:13 PM :
Start Price:
$3.89
MNKD Score:
+41.24
It's not working will with FDA, an the FDA is looking at new medications more closely and not granting approvals, but more trials.
Recs
btthus
(66.20)
Submitted: 2/1/2011 11:00:29 PM :
Start Price:
$4.75
MNKD Score:
-53.98
$5 M in insider buying
Recs
djkumquat
(79.34)
Submitted: 1/28/2011 11:42:14 AM :
Start Price:
$5.11
MNKD Score:
-59.05
insider buy on bad news.
Recs
zzlangerhans
(99.26)
Submitted: 1/27/2011 1:13:27 PM :
Start Price:
$5.18
MNKD Score:
-58.50
So ... tired ... of ... talking ... about ... MannKind ...
There's still lots of KoolAid left in the jug.
Recs
mconway31
(< 20)
Submitted: 1/24/2011 9:32:56 AM :
Start Price:
$5.57
MNKD Score:
-62.75
if there new diabetes inhaler gets approved for sale next year watch this stock take off
Recs
mjguerrera
(< 20)
Submitted: 1/19/2011 7:50:24 PM :
Start Price:
$5.07
MNKD Score:
+59.05
This stock is going to $0.
Recs
BullFighters
(< 20)
Submitted: 1/19/2011 4:54:20 PM :
Start Price:
$5.07
MNKD Score:
+59.05
smell fraud
Recs
stockrockking
(< 20)
Submitted: 1/15/2011 3:10:44 PM :
Start Price:
$9.91
MNKD Score:
-80.50
the fda is in full swing they have a few things to look at but it is going to be approved it will make a diabetics quality of life increase with ease of use also the rapid action of new drug
Recs
Recs
Lumentium
(< 20)
Submitted: 1/13/2011 6:23:32 AM :
Start Price:
$9.27
MNKD Score:
+79.32
not enough disclosures to say otherwise
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 124 : 1 2 3 4 5 6 7 Next »